Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

10630	Companies
225953	Keywords
154496	Articles
119597	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 6 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 7 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 7 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 7 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 7 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 7 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 7 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year 7 months ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year 7 months ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year 7 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform

Accesswire

Published on 06/24/2026 at 20:10, 1 hour 14 minutes ago

Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited
Published on 06/24/2026 at 16:30, 4 hours 54 minutes ago

Development Manager Appointed
Published on 06/24/2026 at 14:45, 6 hours 39 minutes ago

Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 7 hours 24 minutes ago

GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 7 hours 24 minutes ago

Adcore Announces Voting Results from Annual Shareholders Meeting

View all ACCESSWIRE

EQS Group

Published on 06/24/2026 at 20:54, 29 minutes ago

EQS-Adhoc: Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/24/2026 at 18:29, 2 hours 55 minutes ago

Designated Person Notification
Published on 06/24/2026 at 18:29, 2 hours 55 minutes ago

Designated Person Notification
Published on 06/24/2026 at 18:25, 2 hours 58 minutes ago

Huawei Helps Global Carriers Monetize Tokens with Service-Network-Compute Integration
Published on 06/24/2026 at 18:25, 2 hours 59 minutes ago

Annual General Meeting of Highlight Event and Entertainment AG

Les Echos

Published on 06/24/2026 at 19:00, 2 hours 24 minutes ago

ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 3 hours 24 minutes ago

Annual Results 2025-26
Published on 06/24/2026 at 18:00, 3 hours 24 minutes ago

CP résultats annuels 2025-26
Published on 06/24/2026 at 18:00, 3 hours 24 minutes ago

KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 3 hours 39 minutes ago

Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno

View all LES ECHOS COMFI WIRE